Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
A small study finds pazopanib boosts survival in children with advanced Ewing sarcoma when added to standard treatment.
A small study shows pazopanib, a drug originally for kidney cancer, may significantly improve survival for children with advanced Ewing sarcoma when combined with standard treatments.
Among 11 patients, 86% survived two years, and 68% showed no disease progression, far exceeding typical outcomes.
The drug, which blocks tumor blood vessel growth, was well-tolerated with minimal side effects.
Researchers led by Anna Raciborska of Poland’s Warsaw Mother and Child Institute call the results promising but stress the need for larger, controlled trials due to the disease’s rarity.
4 Articles
Un pequeño estudio encuentra que el pazopanib aumenta la supervivencia en niños con sarcoma de Ewing avanzado cuando se añade al tratamiento estándar.